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Abstract
Background: Persistent infection with high-risk human papillomavirus (HPV) is a predominant cause of cervical
cancer, and HPV16 and HPV18 occur in 50% and 20% of cervical cancer cases, respectively. The viral oncogenes E6
and E7 are constitutively expressed by HPV-associated tumour cells and can therefore be used as target antigens
for immunotherapy. In this study, we constructed a recombinant vaccinia virus co-expressing the HPV16/18 E7E6
fusion proteins (rVVJ16/18E7E6) for use as a therapeutic vaccine for the treatment of HPV16
+ and HPV18
+ cancers.
Methods: We constructed a bivalent recombinant vaccinia virus expressing modified E7E6 fusion proteins of HPV
type 16 and 18 (rVVJ16/18E7E6) based on the vaccinia virus Tiantan strain. We then defined the cellular immune
responses to the virus in mice and rhesus monkeys and assessed antitumour efficacy of these responses in mice
using the TC-1 tumour challenge model.
Results: Our data demonstrated that rVVJ16/18E7E6 was able to elicit varying levels of CD8
+ T cell immune
responses and lysis of target cells in mice in response to peptides HPV16E749-57 and HPV18E667-75. Furthermore, the
virus was also able to induce anti-tumour responses in the HPV16
+ TC-1 tumour challenge model, including partial
protection (30-40%) and delayed tumour appearance. In addition, the virus was able to induce immune responses
in rhesus monkeys.
Conclusions: The recombinant vaccinia virus rVVJ16/18E7E6 can generate clear and significant cellular immunity in
both mice and rhesus monkeys. These data provide a basis for the use of this recombinant virus as a potential
vaccine candidate for further study.
1. Background
Cervical cancer is the second most common cause of
cancer death in women worldwide [1]. Infection with
HPV can be demonstrated in 99.7% of cervical cancer
patients [2]. Among the high-risk HPV types isolated
from cervical carcinomas, HPV16 is the most prevalent,
occurring in 46-63% of squamous cell carcinomas, and
HPV18 causes about 37-41% of cervical adenocarcino-
mas worldwide [3]. Two prophylactic HPV vaccines
(Gardasil and Cervarix) [4] have been shown to prevent
most high-risk HPV infections and to minimise the con-
sequences of HPV-associated diseases. However, these
prophylactic vaccines are not predicted to be available
in the near future in developing countries due to eco-
nomic restrictions. In addition, these vaccines have been
shown to be effective only in adolescents with no history
of previous HPV infection and have not shown a thera-
peutic effect against current HPV infection or associated
lesions [4]. Therefore, a large population will remain at
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reasons, the development of a therapeutic vaccine
against high-risk HPV is important.
Various immunotherapeutic strategies have been shown
to be able to elicit strong immune responses that can elim-
inate infected cells and lead to tumour regression. The
oncoproteins E6 and E7 are constitutively expressed in
tumour cells, and their expression is necessary for the
transformation and maintenance of the malignant pheno-
type of the cell [5-7]. Therefore, these viral proteins are
used as target antigens for immunotherapy to treat cervi-
cal cancer and its precursor intraepithelial lesions. Most
studies have focused on therapeutic vaccines against HPV
type 16, and, therefore, the E7 and E6 immunodominant
epitopes for HPV type 16 and the associated immune
responses have been well characterised [8-10]. However,
for HPV type 18, another prevalent high-risk type that has
been implicated in rapidly developing and potentially
aggressive cervical carcinomas [11], there are limited data
on therapeutic vaccines.
The vaccinia virus has been accepted as safe, as it was
used during the WHO smallpox eradication program.
The vaccinia virus Tiantan strain was used as a vaccine
against smallpox in China before 1980, and it is now
widely used and well tolerated as a vector [12,13]. It has
been shown that the Tiantan strain is less virulent when
compared with the pathogenic WR strain [14]. In addi-
tion, the vaccinia virus induces a strong immune
response itself [15]. We previously constructed two
recombinant vaccinia viruses expressing modified E6
and E7 fusion proteins from HPV16 and 18, respec-
tively, using the vaccinia virus Tiantan strain [16]. Our
previous study indicated that these fusion proteins were
able to elicit significant cellular immune responses in
mice. Ideally, a potential vaccine candidate should pro-
tect against as many HPV types as possible so that it
can be used in different patient populations, leading to
cost savings in vaccine production and subsequent clini-
cal application. To accomplish this goal, we have con-
structed a bivalent recombinant vaccinia virus
expressing modified E7E6 fusion proteins from both
HPV types 16 and 18 (rVVJ16/18E7E6) using the vacci-
nia virus Tiantan strain. It is important to test whether
this recombinant candidate vaccine virus can elicit anti-
tumour cellular immune responses in primates. There-
fore, we assessed the immunogenicity of rVVJ16/18E7E6
not only in mice but also in rhesus monkeys. These data
demonstrate that rVVJ16/18E7E6 is able to elicit specific
mouse CTL responses to peptides HPV16E749-57 and
HPV18E667-75 and to induce an antitumour response in
the HPV16
+ TC-1 tumour challenge model. Further-
more, rVVJ16/18E7E6 was able to induce a detectable
cellular immune response in rhesus monkeys.
2. Materials and methods
2.1. Cells and virus
TC-1 cells, generated by co-transformation of primary
C57BL/6 mouse lung epithelial cells with HPV-16 E6
and E7 and an activated ras oncogene [17], were kindly
provided by Dr. T. C. Wu (Johns Hopkins Medical Insti-
tutions, Baltimore, Maryland, USA). Primary chicken
embryonic fibroblasts (CEF) cells were isolated from 7-8
day-old chicken embryos under sterile conditions. The
embryos with head and viscera removed were dissected
and washed 3 times with Hank’sb u f f e ra n dt h e n
digested with 0.25% trypsin in Hank’s buffer at 37°C for
30 minutes. The cell pellets were broken apart by pipet-
ting up and down in minimal essential medium (MEM).
The cells were collected by passing them through a filter
funnel with 8 gauze layers and resuspended in MEM
medium. TC-1 cells and CEF cells were grown in RPMI
1640 medium or MEM medium supplemented with 10%
foetal calf serum, 2 mM glutamine, 1 mM sodium bicar-
bonate, and 100 μg/ml penicillin-streptomycin. Cells
were maintained in humidified air containing 5% CO2 at
37°C.
Virus rVVJ1175 was a modified Tiantan strain vacci-
nia virus expressing the LacZ protein in the thymidine
kinase (TK) region [18]. The recombinant vaccinia virus
rVVJ16E6E7 expressing the E6E7 fusion protein for
HPV16 and rVVJ18E7E6 expressing the E7E6 fusion
protein for HPV18 were constructed in our lab [16].
2.2. Synthetic peptides
Peptide pools consisting of 15 amino acid (AA)-length
peptides overlapping by 4 AA and spanning the entire
sequence of HPV16E6 (158 AA) and HPV18E7 (90 AA),
the D
b binding peptide HPV16E749-57 (RAHYNIVTF)
[19], and the peptide from HPV18E67-75 (KCIDFYSRI)
were commercially synthesised (Beijing Scilight Biotech-
nology Ltd. Co., China). The peptide HPV18E67-75 was
selected as the optimal peptide for responses in C57BL/
6 mice by mapping HPV18E7 peptide pools in a number
of pilot experiments carried out in our lab [16]. All pep-
tides were dissolved in DMSO at 50 mg/ml and used at
5 μg/ml in experiments. PMA (50 ng/ml) and ionomycin
(1 μg/ml) stimulation was used as a positive control for
the generation and detection of antigen-specific T cells
by enzyme-linked immunospot assay (Elispot).
2.3 Construction of the bivalent recombinant vaccinia
virus
2.3.1 Mutagenesis of E7 and E6 for HPV16 and HPV18
The E7 and E6 genes of both HPV types were modified
to inactivate their oncogenic activity and then were
fused in one reading frame. The E7 protein binds Rb via
an L-X-C-X-E motif [7,20]. Therefore, the amino acids
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24C and
26E in HPV16E7 and
27C and
29Ei n
HPV18E7 were mutated to abolish Rb binding and
degradation [21]. For the HPV16E6 protein, mutation at
57Lo r
63C has been shown to destroy the HPV16E6
ability to degrade p53 and immortalise primary epithelial
cells [6,22,23]. Thus,
57Li nH P V 1 6 E 6a n d
65Ci n
HPV18E6 were altered to inactivate their oncogenic
activity. For all mutations, wild type amino acids were
mutated to glycine. In addition, the HPV18 E6 coding
sequence was mutated to eliminate a potential termina-
tion signal (T5NT) for early vaccinia virus transcription
without altering the amino acid coding sequence.
The modified HPV16E7E6 fusion gene was amplified
with mutagenic primers using overlap extension PCR.
Briefly, the mutated version of E7 with the stop codon
removed and the mutated version of E6 with the start
codon deleted were amplified from pUCmE7-1 [24] and
pUCmE6 [24] plasmids, respectively, by using comple-
mentary forward and reverse mutagenic primers. The
complete E7E6 fusion gene was generated by annealing
the two primary PCR products followed by further
rounds of PCR with a set of flanking primers. The pri-
mary PCR products for the modified E7 and E6 frag-
ments were generated using the following primer pairs:
16E7F (5’-CGGAAGATCTACCATGCATGGAGATA-
CACC-3’) with 16E7E6R (5’-CATTGCAGTTCTCTTT
TGGTGTGGTTTCTGAGAACAGATGG-3’)a n d
16E7E6F (5’-CCATCTGTTCTCAGAAACCACAC-
CAAAAGAGAACTGCAATG-3’) with 16E6R (5’-
CTGCAGTTACAGCTGGGTTTC-3’). The complete
E7E6 fusion fragment was generated by annealing the
two primary PCR products followed by further rounds
of PCR with primers 16E7F and 16E6R. The resulting
PCR product was cloned into the pMD18-T vector
(Takara Dalian, China), resulting in pMD18HPV16E7E6,
from which the HPV16E7E6 gene was verified by
sequence analysis. The modified HPV18E7E6 fusion
gene was commercially synthesised and cloned into the
pUC57-T vector (Shanghai Sangon Biological Engineer-
ing Technology & Services Co., Ltd. China) to create
pUC57HPV18E7E6.
2.3.2 Construction of recombinant vaccinia virus
The parent virus used for the construction of the
recombinant vaccinia virus (rVVJ16/18E7E6) was the
rVVJ1175 virus [18]. The plasmid pneoTK16/18E7E6
was constructed and contained the fused HPV16 and
HPV18 E7E6 proteins under the control of the vaccinia-
specific promoters 7.5 K and H6. The double expression
cassettes in pneoTK16/18E7E6 were oriented back-to-
back. The plasmids pJSD and pneoTK were used to con-
struct pneoTK16/18E7E6. Both pJSD and pneoTK,
described in our previous publications [25,26], contained
the vaccinia virus 7.5 K and H6 promoters and flanking
sequences spanning the chosen insertion site in the TK
region of the J fragment within the vaccinia virus gen-
ome. In order to construct pneoTK16/18E7E6,
HPV16E7E6 was excised from the plasmid
pMD18HPV16E7E6 by digestion with Bgl II and Sma I
and cloned into the BamH Ia n dSma I sites of plasmid
pJSD under the control of the vaccinia specific 7.5 K
promoter, giving rise to pJSDHPV16E7E6. Subsequently,
HPV18E7E6 was excised from pUC57HPV18E7E6 by
double digestion with Bgl II and Cla I and inserted into
pJSDHPV16E7E6 downstream of the H6 promoter at
the Bgl II and Cla I sites to generate pJSDHPV16/
18E7E6. Finally, the double expression cassettes were
excised from pJSDHPV16/18E7E6 by Sma Ia n dCla I
a n dc l o n e di n t op n e o T Ka tt h eSma Ia n dCla It oc r e -
ate pneoTK16/18E7E6 (as shown in Figure 1A). The
final virus vector (rVVJ16/18E7E6) expressing HPV16
and 18 E7E6 fusion proteins was constructed through
homologous recombination using rVVJ1175 viral DNA
and the plasmid pneoTK16/18E7E6 in CEF cells. The
rVVJ16/18E7E6 virus was then purified and propagated.
2.3.3 Polymerase chain reaction (PCR)
CEF cells were infected with the recombinant vaccinia
virus rVVJ16/18E7E6 or control virus rVVJ1175 at a
multiplicity of infection (MOI) = 1 and incubated for 24
hours. The infected cells were then harvested. Viral
DNA was extracted using the DNeasy Blood & Tissue
Kit (Qiagen, Germany). Subsequently, PCR (30 cycles of
94°C for 40 seconds, 58°C for 30 seconds and 72°C for
90 seconds) was performed using two pairs of primers
containing the promoter sequence and the bilateral
sequence of the recombinant vaccinia viruses (P7.5 for
5’-CACTAATTCCAAACCCACCC-3’; P7.5 R for 5’-
GGGTGGGTTTGGAATTAGTG-3’; TKR for 5’-
CCATCGAGTGCGGCTAC-3’; TKL for 5’-CTATGT-
GATGTCTTGGAATC-3’). All amplified DNA frag-
ments were sequenced to confirm that the rVVJ16/
18E7E6 contained the correct target gene.
2.3.4 Western blotting
CEF cells were infected with the recombinant vaccinia
virus rVVJ16/18E7E6 or control virus rVVJ1175 at MOI
= 10 and incubated for 24 hours. The infected cells
were then harvested, washed once with PBS and resus-
pended in protein loading buffer (50 mM Tris-Cl pH
6.8, 2% SDS, 10% glycerol, 5% b-mercaptoethanol and
0.025% Bromophenol blue). The cellular extracts were
separated by 12% sodium dodecyl sulphate polyacryla-
mide gel electrophoresis (SDS-PAGE), electrophoreti-
cally transferred onto nitrocellulose membranes
(Amersham, UK) and blocked in PBST/5% skim milk.
After blocking, the membranes were incubated over-
n i g h ta t4 ° Cw i t hm o u s ea n t i - H P V 1 6E 7m o n o c l o n a l
antibody (prepared in-house) and other commercially
available antibodies (goat anti-HPV16 E6, goat anti-
HPV18 E6 or goat anti-HPV18 E7 polyclonal antibodies,
Zhao et al. Virology Journal 2011, 8:302
http://www.virologyj.com/content/8/1/302
Page 3 of 11Santa Cruz, USA). After five washes with PBST, the
membranes were incubated with anti-mouse or anti-
goat immunoglobulin G-horseradish peroxidase (IgG-
HRP, Sigma, USA) for 2 hours at 4°C and washed again
with PBST. All antibodies were diluted in PBST/5%
skim milk. The membranes were then detected using a
chemiluminescence ECL kit (Pierce, USA).
2.4 Mouse studies
2.4.1 Mice
Specific pathogen-free female C57BL/6 aged 6-8 weeks
old were purchased from the Institute of Laboratory
Animal Sciences, Chinese Academy of Medical Sciences
& Peking Union Medical College (CAMS & PUMC) and
maintained under pathogen-free conditions at the ani-
mal facilities of Institute of Materia Medica, CAMS &
PUMC.
2.4.2 Mouse IFN-g Elispot assay
Groups of C57BL/6 mice (five animals per group) were
immunised intraperitoneally with 1 × 10
7 pfu
recombinant vaccinia virus rVVJ16/18E7E6, virus
rVVJ16E6E7, virus rVVJ18E7E6, virus rVVJ1175 or PBS.
Mice were boosted once with the same dose two weeks
later. Splenocytes were harvested for the analysis of
HPV-specific cellular immune responses by Elispot and
for intracellular cytokine staining ten or twelve days
after the last vaccination.
The mouse IFN-g Elispot assay was carried out
according to the manufacturer’s instructions (U-CyTech,
Netherlands). Briefly, wells of PVDF membrane-bot-
tomed plates (Millipore, Netherlands) were coated with
the anti-mouse IFN-g capture antibody overnight at 4°C.
After washing and blocking with blocking buffer R for 1
hour at 37°C, freshly isolated splenocytes (5 × 10
5) were
added to the wells with or without peptides in medium
containing RPMI 1640, 10% FCS, 2 mM glutamine, 1
mM sodium bicarbonate and 100 μg/ml penicillin-strep-
tomycin. Individual peptides or peptide pools were
added at 5 μg/ml. For positive controls, PMA (50 ng/
ml) and Ionomycin (1 μg/ml) were added to the Elispot
pneoTK16/18E7E6
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Figure 1 Construction of recombinant vaccinia virus rVVJ16/18E7E6 and confirmation of the fusion genes by PCR and western blot
analyses. A Schematic diagram of plasmid pneoTKJ16/18E7E6, which contains two expression cassettes in a back-to-back orientation, flanked by
vaccinia virus TK region sequences. The expression cassette on the left consists of HPV18E7E6 under the control of the H6 promoter, and the
expression cassette on the right is comprised of HPV16E7E6 led by the 7.5 K promoter. Both H6 and 7.5 K promoters are vaccinia-specific
promoters. B Schematic diagram of recombinant vaccinia virus rVVJ1175 (top) and rVVJ16/18E7E6 (bottom). Virus rVVJ1175 was a Tiantan strain
vaccinia virus with a lacZ gene led by a p11 promoter inserted into the TK region. Virus rVVJ16/18E7E6 was derived from virus rVVJ1175, in
which the lacZ expression cassette was replaced by the double expression cassettes for HPV16 and 18 E7E6 fusion proteins. C PCR analyses of
the HPV sequences in CEFs infected with rVVJ1175 or rVVJ16/18E7E6 using the primers TKL and P7.5 R and the primers P7.5 and TKR. D Western
blot analyses to detect the expression of HPV16E7E6 and HPV18E7E6 fusion proteins in CEFs infected with rVVJ1175 or rVVJ16/18E7E6 using the
specific antibodies against HPV16E6, HPV16E7, HPV18E6, or HPV18E7. The marker shown is the low molecular weight protein marker (Institute of
Biochemistry and Cell Biology Shanghai Institute for Biological Sciences, China).
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Page 4 of 11wells. Plates were then incubated at 37°C for 24-28
hours. After washing, biotinylated detection antibody
was added to wells, and plates were then incubated for
1 hour at 37°C. After further washing, streptavidin-
horseradish peroxidase was added for a further 1 hour
incubation at 37°C. After washing again, spots were
revealed by adding AEC (3-amino-9-ethylcarbazole) sub-
strate solution to yield a coloured spot after a 20-40
minutes incubation at room temperature in the dark.
Finally, colour development was stopped by thoroughly
rinsing with tap water.
The number of spots was analysed with a fully auto-
mated computer-assisted video imaging analysis system
(Bioreader 4000, Germany). The average number of
spot-forming cells (SFC) was adjusted to 1 × 10
6 spleno-
cytes for data display.
2.4.3 Intracellular cytokine staining and flow cytometry
analysis
The splenocytes from the mice immunised with virus
rVVJ16/18E7E6 and virus rVVJ1175 were cultured in 96
well plates at a concentration of 2 × 10
6 cells/well and
stimulated with or without 5 μg/ml of HPV16E749-57
peptide or HPV18E667-75 peptide for 5 hours. For the last
2 hours of stimulation, 10 μM monensin was added to
block the secretion of cytokines. Cells were then washed
and stained for cell surface markers CD8 and CD4. After
fixation with 4% paraformaldehyde and permeabilisation
with 0.15% saponin, cells were then stained with APC-
conjugated anti-IFN-g antibody. The labelled cells were
analysed on a FACS Calibur cytometer.
2.4.4 In vivo cytotoxicity assay
The in vivo cytotoxicity assay was performed as described
by Barber et al. [27]. In brief, splenocytes from naive
C57BL/6 mice were labelled with either 1 μMo r1 0μM
of the cytosolic dye CFSE. The cells labelled with 1 μM
CFSE were left unpulsed with peptide, and the cells
labelled with 10 μMC F S Ew e r ep u l s e dw i t h5μg/ml
HPV16E749-57 or HPV18E667-75 peptide for 4 hours.
N e x t ,t h ep u l s e da n du n p u l s e dc e l l sw e r em i x e di na1 : 1
ratio and transferred intravenously (10 million cells for
each mouse) into the mice vaccinated with virus rVVJ16/
18E7E6 or virus rVVJ1175 or into uninfected mice. After
15 hours of in vivo killing, splenocytes were isolated and
analysed by flow cytometry to measure target cell clear-
ance. The percentage of specific killing was calculated as
follows: 100-[(% peptide-pulsed in infected/% unpulsed
in infected)/(% peptide-pulsed in uninfected/% unpulsed
in uninfected)] × 100.
2.4.5 In vivo tumour protection and treatment experiments
using the TC-1 tumour cell line
For in vivo tumour protection experiments, C57BL/6
mice (ten animals per group) were immunised twice
intraperitoneally at two-week intervals with 1 × 10
7 pfu
recombinant vaccinia virus rVVJ16/18E7E6, virus
rVVJ16E6E7, virus rVVJ1175 or PBS. Two weeks after
the last vaccination, mice were challenged subcuta-
neously in the groin with 1.2 × 10
4 TC-1 tumour cells.
In the treatment experiments, C57BL/6 mice were chal-
lenged with 1 × 10
4 TC-1 cells at day 0 and then vacci-
nated at day 1 and day 11 with the same dose as that
used in the tumour protection experiment. Tumour
development was monitored twice a week during a 50
day follow-up.
2.5 Rhesus monkey studies
2.5.1 Rhesus monkeys and immunisation
Rhesus monkeys aged between 4 and 5 years old and
weighing between 2 and 3 kg were used in this study.
These monkeys were kept indoors in individual cages
with artificial lighting (12 h dark/12 h light cycle) and
air-conditioning that maintained the ambient tempera-
ture at 21-25°C. All animals were routinely examined by
trained veterinarians and cared for in accordance with
the approved guidelines.
In this study, a total of 9 rhesus monkeys were used
and randomly divided into three groups without regard
for gender (three monkeys/per group). The monkeys
were immunised twice intradermally in the left leg with
PBS (numbers 1, 2 and 3), rVVJ1175 (numbers 4, 5 and
6) or rVVJ16/18E7E6 (numbers 7, 8 and 9). They were
primed with 1 × 10
7 pfu recombinant vaccinia virus at
day 0 and boosted with 5 × 10
7 pfu recombinant vacci-
nia virus at day 11. Peripheral blood mononuclear cells
(PBMCs) of all three groups of vaccinated monkeys
were analysed for HPV-specific cellular immunity by
IFN-g Elispot assays at days -2 and 53.
2.5.2 Monkey IFN-g Elispot assay
The monkey IFN-g Elispot assay was carried out accord-
ing to the manufacturer’s instructions (U-CyTech, Neth-
erlands), which was similar to the protocol for mouse.
Briefly, the PBMCs from rhesus monkeys were freshly
isolated and added at 3 × 10
5/well with or without pep-
tide pools (pools for E7 or E6 of HPV16 and HPV18) at
5 μg/ml into a PVDF membrane-bottomed plate pre-
coated with anti-monkey IFN-g capture antibody. The
plates were then incubated for 24-28 hours at 37°C
prior to the detection of specific T cell responses and
then developed as for mouse Elispot assays, except that
an anti-monkey detection antibody was added. Finally,
the average number of SFC was adjusted to 1 × 10
6
PBMC for data display.
2.6 Statistical analyses
Data are presented as means and standard errors. Statis-
tical analyses were performed with GraphPad Prism ver-
sion 5.01 (GraphPad Software, Inc., 2007). Comparisons
of mean immune responses among groups of mice were
performed by analyses of variance with an unpaired t
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were performed with Fisher’s exact test, and compari-
sons of survival curves were performed with the log-
rank test. In all cases, P values of less than 0.05 were
considered to be significant.
3. Results
3.1 Construction of recombinant vaccinia virus
The recombinant vaccinia virus rVVJ16/18E7E6 expres-
sing HPV 16 and 18 E7E6 fusion proteins was con-
structed by homologous recombination in CEF cells
with the shuttle plasmid pneoTK16/18E7E6 and the par-
ent virus rVVJ1175. The resulting rVVJ16/18E7E6 was
purified and amplified. Figure 1B shows the structures
of rVVJ16/18E7E6. The target genes were integrated
into the TK region of the J fragment within the vaccinia
virus genome. The fused, modified HPV16E7E6 gene
under the control of the vaccinia-specific 7.5 K promo-
ter was in a back-to back orientation with the fused,
modified HPV18E7E6 gene under the control of the vac-
cinia-specific H6 promoter.
Two pairs of primers (P7.5/TKR and P7.5R/TKL) with
the promoter sequence and the bilateral sequence of
recombinant vaccinia virus were used to amplify the tar-
get genes and flanking sequences by PCR of the
extracted virus DNA. The amplified PCR fragments for
the two pairs of primers shown in Figure 1C were 1011
bp and 1197 bp, respectively. The real and predicted
sizes for both PCR products appeared to be consistent.
The sequencing results of the PCR products confirmed
that the E7E6 fusion genes were correct and integrated
into the right region within the rVVJ16/18E7E6 genome.
No comparable fragments were amplified from the con-
trol rVVJ1175 or the blank.
Cells infected with rVVJ16/18E7E6 were analysed by
western blot using specific antibodies for the HPV16/18
E7 and E6 proteins. Figure 1D shows that rVVJ16/
18E7E6 expressed proteins of the size expected for the
HPV16 E7E6 fusion protein (30 kD) and HPV18 E7E6
fusion protein (31 kD), whereas the control rVVJ1175
did not produce these proteins.
Furthermore, the genetic stability of bivalent rVVJ16/
18E7E6 was tested after 10 passages in CEF, and the
results show that the exogenous gene sequences and
fusion protein expression levels were stable and that the
rates of gene deletion were from zero to 2% (data not
shown).
3.2 T cell immune responses against HPV16 E7- and
HPV18 E6-derived peptides after immunisation with
rVVJ16/18E7E6 in mice
To test the specific T cell immune responses induced by
recombinant vaccinia virus, C57BL/6 mice were injected
with rVVJ16/18E7E6, rVVJ16E6E7, rVVJ18E7E6,
rVVJ1175 or PBS. The splenocytes from immunised
mice were tested directly ex vivo in IFN-g Elispot assays
against peptides HPV16E749-57 and HPV18E667-75 and
peptide pools of both HPV16 E6 and HPV18 E7. No sig-
nificant IFN-g responses were detected for the HPV16
E6 and HPV18 E7 peptide pools in any of the immu-
nised mice. However, as shown in Figure 2, rVVJ16/
18E7E6 was able to induce specific cellular immune
responses against peptides HPV16E749-57 and
HPV18E667-75 in C57BL/6 mice after two immunisa-
tions, and the average numbers of IFN-g-positive spots
were 63.6 ± 16 and 881.4 ± 96 SFC/10
6 splenocytes.
The immune responses were significantly increased
when compared with the control mice immunised with
rVVJ1175 or PBS (P < 0.05 and P < 0.001, respectively),
and they were similar to the immune responses in mice
immunised with virus rVVJ16E6E7 (HPV16E749-57, 61.0
± 8.7) and with virus rVVJ18E7E6 (HPV18E667-75,8 5 8 . 4
± 98).
To determine whether the IFN-g production was
induced by CD8
+ T cells, intracellular cytokine staining
was performed. Splenocytes from mice immunised with
virus rVVJ16/18E7E6 and virus rVVJ1175 were stimu-
lated in vitro with peptides HPV16E749-57 and
HPV18E667-75. As shown in Figures 3A and 3B, the fre-
quency of specific IFN-g producing CD8
+ Tc e l l sw e r e
63.4 ± 12 and 1188 ± 485 per 10
6 splenocytes in the
mice immunised with virus rVVJ16/18E7E6; these fre-
quencies were significantly increased compared with
mice immunised with rVVJ1175 (22 ± 11 (P < 0.05) and
34.5 ± 6 (P < 0.001), respectively). Specific IFN-g produ-
cing CD4
+ T cells were not detected in any group of
immunised mice (data not shown).
Figure 2 Specific T cell responses were tested directly ex vivo
in IFN-g Elispot assays against peptides HPV16E749-57 and
HPV18E6 67-75 . C57BL/6 mice (n = 4 per group) were immunised
with PBS, rVVJ1175, rVVJ16E6E7, rVVJ18E7E6 or rVVJ16/18E7E6. Five
hundred thousand splenocytes were incubated ex vivo with or
without 5 μg/ml of HPV16E749-75 or HPV18E667-75 peptides. Plates
were incubated for 24-28 hours at 37°C. Background IFN-g
production was generally found for the medium without peptides
to be below 5 spots/million splenocytes. Asterisks represent
statistically significant differences relative to the rVVJ1175 virus
control (* p < 0.05, ** p < 0.001). Data shown are means ± standard
deviations for three independent experiments.
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+
T cells in mice immunised with rVVJ16/18E7E6, we
examined killing cells in vivo by transferring target cells
pulsed with peptides HPV16E749-57 and HPV18E667-75
into immunised mice. As shown in Figure 4A and 4B,
13.56% of the HPV16E749-57 peptide-pulsed targets and
71.96% of the HPV18E667-75 peptide-pulsed targets were
eliminated in mice immunised with virus rVVJ16/
18E7E6. Only 4.2% and 1.65% targets cells were killed in
control mice immunised with rVVJ1175. These differ-
ences were statistically significant, and P values were
less than 0.05 and 0.001.
Taken together, these results indicated HPV16E7 and
HPV18E6 specific cellular immune responses were
induced in mice immunised with virus rVVJ16/18E7E6.
3.3 In vivo tumour protection and treatment experiments
using the TC-1 tumour
In order to assess the prophylactic antitumour efficacy
of rVVJ16/18E7E6 vaccination in the HPV16
+ TC-1
tumour model where T cells specific for the immunodo-
minant D
b HPV16E749-57 epitope would participate,
C57BL/6 mice were vaccinated twice with rVVJ16/
18E7E6, rVVJ16E6E7, rVVJ1175 or PBS at two-week
Figure 3 Intracellular cytokine staining with flow cytometry analysis to determine the proportion of specific IFN-g -expressing CD8
+ T
cells. Splenocytes from mice (n = 3 per group) immunised with virus rVVJ16/18E7E6 and virus rVVJ1175 were cultured and stimulated with
either HPV16E749-57 or HPV18E667-75 peptide. Splenocytes without peptide stimulation were used as a negative control. The splenocytes were
stained for both CD8
+ and intracellular IFN-g (A) Representative intracellular cytokine staining. The number of CD8
+ IFN-g
+ T cells in 1 × 10
6
splenocytes are indicated in the upper right corner. (B) Bar graph depicting the number of specific IFN-g expressing CD8
+ T cells per 1 × 10
6
splenocytes (mean ± SD) following in vitro stimulation in two independent experiments. Asterisks represent statistically significant differences
relative to the rVVJ1175 virus control (* p < 0.05, ** p < 0.001).
Figure 4 In vivo cytotoxicity assays to determine the specific lytic potential of effector CD8
+ T cells in mice immunised with rVVJ16/
18E7E6. (A) Target cells were transferred into mice (n = 3 per group) immunised with virus rVVJ16/18E7E6 or virus rVVJ1175 or into naïve mice.
Numbers represent the percentage of target cells killed. (B) The bar graph indicates the percentage of specific killing for peptides HPV16E749-57-
and HPV18E667-75 -pulsed targets from the indicated groups of mice. Data are given as mean ± SD of two independent experiments. The
percentage of specific killing was calculated as follows: 100-[(% peptide pulsed in infected/% unpulsed in infected)/(% peptide pulsed in
uninfected/% unpulsed in uninfected)] × 100. Asterisks represent statistically significant differences relative to the rVVJ1175 virus control (* p<
0.05, ** p < 0.001).
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4 TC-1 tumour
cells two weeks after the last vaccination. As shown in
Figure 5A, all control mice receiving either rVVJ1175 or
PBS developed tumours within 18 days following
tumour challenge. However, the mice immunised with
rVVJ16/18E7E6 delayed tumour development and were
partially protected (30%, P = 0.039) against the challenge
with TC-1 tumour cells. Similar results were observed in
mice immunised with rVVJ16E6E7, which can provide
40% protection (P = 0.011).
We aimed to construct rVVJ16/18E7E6 to develop a
therapeutic vaccine for the treatment of HPV16
+ and
HPV18
+ cancers, so we examined whether the recombi-
nant vaccinia virus could be used in a therapeutic set-
ting. C57BL/6 mice were inoculated with 1 × 10
4 TC-1
tumour cells on day 0. Mice were then immunised and
boosted with rVVJ16/18E7E6, rVVJ16E6E7, rVVJ1175 or
PBS at days 1 and 11 after tumour cell inoculation. As
shown in Figure 5B, the results were similar to the
prophylactic antitumour efficacy for rVVJ16/18E7E6.
Mice in the group treated with rVVJ16/18E7E6 or
rVVJ16E6E7 post-TC-1 cell challenge appeared to have
delayed tumour development and partial protection
(40% or 30%). All control mice receiving either
rVVJ1175 or PBS developed tumours within 28 days in
this therapeutic setting. These difference were statisti-
cally significant compared with the control virus
rVVJ1175 or PBS (P < 0.05).
3.4 Vaccination with rVVJ16/18E7E6 generates E6- and
E7-specific T cell immune responses in rhesus monkeys
As specific T cell immune responses against peptides
HPV16E7 and HPV18E6 were induced in immunised
mice, we examined whether our recombinant vaccinia
virus could elicit anti-tumour cellular immune responses
in non-human primates. Therefore, we tested the immu-
nogenicity of rVVJ16/18E7E6 in rhesus monkeys. The
monkeys were immunised twice with the virus at days 0
(1 × 10
7 p f u )a n d1 1( 5×1 0
7 pfu). Control monkeys
received rVVJ1175 or PBS. PBMCs from the monkeys
were analysed for HPV-specific cellular immunity
against peptide pools from E7 or E6 of HPV16 and
HPV18 by IFN-g Elispot assays at days -2 and 53.
There were no detectable T cellular immune
responses specific for HPV peptide pools in any of the
monkeys on days -2. Figure 6A shows the IFN-g
responses on day -2 for three individual monkeys (num-
bers 1, 4 and 7) from each of the three groups, which
represents the background immune response (< 20 SFC/
10
6 PBMCs).
H o w e v e r ,t h e r ew e r es i g n i f i c a n ts p e c i f i ci m m u n e
responses detected in the monkeys immunised with
rVVJ16/18E7E6 at day 53. As shown in Figure 6B, the
responses for cells stimulated with medium without
peptides ranged from 0 to 17 SFC/10
6 PBMCs. Specific
T cell immune responses against the four peptide pools
were induced in the rhesus monkeys vaccinated with
rVVJ16/18E7E6, among which responses to peptide
pools HPV16 E7 and E6 were detected in one monkey
(number 7), and the average number of IFN-g spots
were 83 ± 35 and 77 ± 38 SFC/10
6 PBMCs. Responses
to peptide pool HPV18 E7 occurred in two monkeys
(numbers 7 and 8) and the spots were 192 ± 37 and 144
±3 9S F C / 1 0
6 PBMCs. Responses to peptide pool
HPV18 E6 were observed in two monkeys (numbers 7
and 9), and spots were 121 ± 14 and 83 ± 38 SFC/10
6
PBMCs. Among the three monkeys generating specific
responses, one (number 7) responded to all 4 peptide
pools. In contrast, no specific responses were detected
in control monkeys injected with rVVJ1175 or PBS.
Hence, immunisation of rhesus monkeys with rVVJ16/
18E7E6 was able to elicit E7 and E6 specific cellular
responses for HPV16 and HPV18, respectively.
Figure 5 In vivo tumour protection and treatment experiments
using TC-1 tumour cells with recombinant vaccinia virus. Panel
A: in vivo tumour protection experiments; C57BL/6 mice (n = 10 per
group) were immunised intraperitoneally twice at two weeks
interval with 1 × 10
7 pfu recombinant vaccinia virus rVVJ16/18E7E6
and rVVJ16E6E7, control virus rVVJ1175 or PBS. Two weeks after the
last vaccination, mice were challenged subcutaneously in the groin
with 1.2 × 10
4 TC-1 tumour cells. Panel B: the treatment
experiments; C57BL/6 mice (n = 10 per group) received 1 × 10
4 TC-
1 cells on day 0 and were vaccinated with in same groups and
dose as used in panel A at days 1 and 11. Tumour development
was monitored twice a week during a 50-day follow-up. The data in
this figure are from one of two similar experiments.
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Persistent infection with high-risk human papillomavirus
(HPV) is a predominant cause of cervical cancer, and
HPV16 and HPV18 occur in 50% and 20% of cervical
cancer cases, respectively[3]. Therefore, the development
of therapeutic vaccines is important for the treatment of
HPV-associated neoplasms, such as cervical cancer and
its intraepithelial precursor lesions. In this study, we
constructed a recombinant vaccinia virus (rVVJ16/
18E7E6) co-expressing the HPV16/18 E7E6 fusion pro-
teins as a candidate therapeutic vaccine to protect
against both HPV16 and HPV18. For safety future clini-
cal application, we modified the E6 and E7 genes to
inactivate their oncogenic activity and fused them in
one reading frame.
Because cell-mediated immunity appears to be impor-
tant in controlling HPV infections and disease, we
selected a vaccinia virus of the Tiantan strain to con-
struct the recombinant vaccinia virus rVVJ16/18E7E6
for the delivery of the HPV gene sequences. We
expected that the recombinant virus would be able to
induce a strong cellular immune response to control or
eliminate HPV-infected cells and thus treat the HPV-
associated neoplasms. In this study, we showed that the
recombinant virus encoded the HPV DNA sequences in
the expected configuration and that the heterologous
coding sequences were successfully expressed as protein
products in the virus-infected cells. We also showed
that a specific T cell response to peptide HPV16 E749-57
c o u l db ee l i c i t e di nt h eC 5 7 B L / 6m i c ei m m u n i s e dw i t h
the recombinant vaccinia virus rVVJ16/18E7E6 using
two in vitro assays. Furthermore, we also showed that
specific lytic activity could be detected in immunised
mice in vivo and resulted in antitumour responses in
HPV16
+ TC-1 tumour protection and treatment experi-
ments, including delayed tumour appearance and 30-
40% protection. These results were similar to the
immune responses to rVVJ16E6E7 (one recombinant
vaccinia virus expressing HPV16 E6E7 fusion protein).
These data suggest that peptide HPV16 E749-57,
described by other studies as the immunodominant epi-
tope associated with MHC class I of the H-2
b haplotype,
could be efficiently presented in C57BL/6 mice immu-
nised with rVVJ16/18E7E6.
Vaccination with virus rVVJ16/18E7E6 in C57BL/6
mice was able to induce significant CD8
+ T cell
responses against peptide HPV18E667-75,a ss h o w nb yin
vitro or in vivo assays, which indicated that the
HPV18E7E6 fusion protein was effectively processed in
C57BL/6 mice. This was unexpected because
McCarthy’s studies indicated that peptide HPV18E667-75
was only able to bind to HLA-A2 molecules in HLA-
A2/K
b mice immunised with a HPV18E6 DNA vaccine
[28]. Therefore, we hypothesized that this peptide may
be presented in humans as well as in the C57BL/6 mice.
Although peptide HPV18E667-75 was different from two
other reported peptides (the dominant epitope was E650-
64 and the subdominant epitope was E657-71) described
by mapping HPV18E6 peptide pools in C57BL/6 mice
immunised with a HPV18E6E7 DNA vaccine carried out
by Yan and colleagues [29], this peptide overlapped with
the peptide E657-71 and was adjacent to the peptide
E650-64. This difference may be explained by the fact
that the different gene fusion procedure used in our
study may have altered antigen presentation of
HPV18E6.
We did not detect T cell responses against the
HPV16E6 and HPV18E7 antigens. We hypothesize that
these epitopes may not be effectively processed due to
either the E7E6 gene fusion method or to the fact that
they elicited T cell responses that were too low to be
detected. Importantly, although there is no animal chal-
lenge model available for HPV18, rhesus monkeys
immunised with rVVJ16/18E7E6 could elicit E7- and
Figure 6 Specific T cell responses were tested directly ex vivo
in IFN-g Elispot assays with PBMCs in rhesus monkeys. The
rhesus monkeys (n = 3 per group) were immunised intradermally in
the left leg twice with PBS (numbers 1, 2 and 3), rVVJ1175 (numbers
4, 5 and 6) or rVVJ16/18E7E6 (numbers 7, 8 and 9). The monkeys
were primed with 1 × 10
7 pfu recombinant vaccinia virus at day 0
and boosted with 5 × 10
7 pfu recombinant vaccinia virus at day 11.
PBMCs from all three groups of vaccinated monkeys were analysed
for HPV-specific cellular immunity against medium (without
peptides) and peptide pools E7 or E6 of HPV type 16 and 18 by
IFN-g Elispot assays at days -2 and 53.
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Page 9 of 11E6-specific cellular responses to both HPV16 and
HPV18. In addition, when monkeys were boosted with
one protein-based vaccine HPV16L2E7E6 that was
expressed efficiently in a prokaryotic system and purified
by using ion exchange chromatography, the responses to
the HPV16 E7 and E6 peptide pools were able to be
improved in two monkeys.
In conclusion, we observed that the recombinant vac-
cinia virus rVVJ16/18E7E6 was able to generate signifi-
cant and functional cellular immunity in both mice and
rhesus monkeys. These data provide a basis to proceed
with the recombinant virus as a potential vaccine candi-
date in further studies.
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